StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Organon — Nasonex (mometasone) U.S. sales by Quarter

Organon — Nasonex (mometasone) U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Organon — Nasonex (mometasone) U.S. sales: $0M in Q2 2026. That is the lowest of the 22 quarters on record here.

Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
17
Documents cited below

Where the Q2 2026 figure comes from

Source: Organon & Co. SEC Filing (0001628280-26-051230) ↗

Reported in Organon & Co. Form 10-Q / 10-K (CIK 0001821825).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOrganon — Nasonex (mometasone) U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20260–Organon & Co. SEC Filing (0001628280-26-051230) ↗
Q1 2026Mar 31, 20260–Organon & Co. SEC Filing (0001628280-26-029532) ↗
Q4 2025Dec 31, 20250–Organon & Co. SEC Filing (0001628280-26-011125) ↗
Q3 2025Sep 30, 20250–Organon & Co. SEC Filing (0001628280-25-050795) ↗
Q2 2025Jun 30, 20250–Organon & Co. SEC Filing (0001821825-25-000066) ↗
Q1 2025Mar 31, 20250–Organon & Co. SEC Filing (0001821825-25-000023) ↗
Q4 2024Dec 31, 20240–Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2024Sep 30, 20240–Organon & Co. SEC Filing (0001821825-24-000108) ↗
Q2 2024Jun 30, 20240–Organon & Co. SEC Filing (0001821825-25-000066) ↗
Q1 2024Mar 31, 20240–Organon & Co. SEC Filing (0001821825-25-000023) ↗
Q4 2023Dec 31, 20230-100.0%Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2023Sep 30, 20230–Organon & Co. SEC Filing (0001821825-24-000108) ↗
Q2 2023Jun 30, 20230–Organon & Co. SEC Filing (0001821825-24-000083) ↗
Q1 2023Mar 31, 20230-100.0%Organon & Co. SEC Filing (0001821825-24-000056) ↗
Q4 2022Dec 31, 20221,000,0000.0%Organon & Co. SEC Filing (0001821825-25-000006) ↗
Q3 2022Sep 30, 20220–Organon & Co. SEC Filing (0001821825-23-000013) ↗

Cite this data

StockData. (2026). Merck Organon — Nasonex (mometasone) U.S. sales ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn-nasonex-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.